Indinavir
- Generic Name
- Indinavir
- Brand Names
- Crixivan
- Drug Type
- Small Molecule
- Chemical Formula
- C36H47N5O4
- CAS Number
- 150378-17-9
- Unique Ingredient Identifier
- 9MG78X43ZT
- Background
A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem]
- Indication
Indinavir is an antiretroviral drug for the treatment of HIV infection.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Safety and Tolerance of Indinavir Plus Ritonavir in HIV-Positive Patients Failing Therapy With Amprenavir, Nelfinavir, or Saquinavir
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 50
- Registration Number
- NCT00001133
- Locations
- 🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸Ucsf Aids Crs, San Francisco, California, United States
🇺🇸Alabama Therapeutics CRS, Birmingham, Alabama, United States
Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2013-07-29
- Target Recruit Count
- 300
- Registration Number
- NCT00000882
- Locations
- 🇺🇸
State of MD Div of Corrections / Johns Hopkins Univ Hosp, Baltimore, Maryland, United States
🇺🇸Northwestern Univ Med School, Chicago, Illinois, United States
🇺🇸Cook County Hosp, Chicago, Illinois, United States
Effectiveness of Anti-HIV Drugs in Patients Who Have Not Received Previous Anti-HIV Drugs During Different Stages of HIV Infection
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-02
- Target Recruit Count
- 24
- Registration Number
- NCT00006443
- Locations
- 🇺🇸
Michael S. Saag, Birmingham, Alabama, United States
A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 399
- Registration Number
- NCT00000916
- Locations
- 🇺🇸
Harbor-UCLA Med. Ctr. CRS, Torrance, California, United States
🇺🇸Weiss Memorial Hosp., Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital ACTG CRS, Boston, Massachusetts, United States
A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 475
- Registration Number
- NCT00000912
- Locations
- 🇺🇸
USC Univ Hosp & Ambulatory Hlth Care Ctr / USC Med Ctr, Los Angeles, California, United States
🇺🇸Emory Univ, Atlanta, Georgia, United States
🇺🇸UCLA CARE Ctr, Los Angeles, California, United States
Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2016-12-14
- Target Recruit Count
- 16
- Registration Number
- NCT00000875
- Locations
- 🇺🇸
The Ctr For Blood Research Inc, Boston, Massachusetts, United States
Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 240
- Registration Number
- NCT00001083
- Locations
- 🇺🇸
Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States
🇺🇸Univ of Miami (Pediatric), Miami, Florida, United States
🇺🇸North Shore Univ Hosp, Great Neck, New York, United States
A Randomized Trial of L-735,524, An Inhibitor of the HIV Protease Enzyme, and Interleukin-2 in Persons Infected With HIV (NOTE: Only For Patients Who Previously Completed NIAID 93 CC-113)
- Conditions
- HIV Infections
A Study to Evaluate the Safety and Tolerance of Combination Anti-HIV Drug Therapy (Indinavir, Lamivudine, and Zidovudine) in HIV-Positive Pregnant Women and Their Infants
- Conditions
- HIV InfectionsPregnancy
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 24
- Registration Number
- NCT00000944
- Locations
- 🇺🇸
Montefiore Med. Ctr. - AECOM, Bronx, New York, United States
🇺🇸Jacobi Med. Ctr., Bronx, New York, United States
🇺🇸HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States
Study of How Indinavir (an Anti-HIV Drug) and Rifabutin (a Drug Used to Treat MAC, an HIV-Associated Disease) Interact in HIV-Positive and HIV-Negative Adults
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 31
- Registration Number
- NCT00000877
- Locations
- 🇺🇸
Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸Univ of Southern California / LA County USC Med Cntr, Los Angeles, California, United States
🇺🇸Univ of Miami School of Medicine, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.